Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/24/2021 | $17.00 | Buy | Chardan Capital Markets |
| 11/10/2021 | Outperform | Cowen |
SC 13G/A - Better Therapeutics, Inc. (0001832415) (Subject)
SC 13D/A - Better Therapeutics, Inc. (0001832415) (Subject)
SC 13D/A - Better Therapeutics, Inc. (0001832415) (Subject)
One million prescriptions for AspyreRx will be offered to patients in underserved communities disproportionately affected by type 2 diabetes Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced a major partnership with the American College of Lifestyle Medicine's (ACLM) National Training Initiative (NTI), aimed at improving diabetes outcomes in underserved communities across the United States. Through this partnership, Better Therapeutics is committed to making one million prescriptions of its U.S. Food and Drug Administration (FDA)-authorized product, AspyreRx, available to support
Industry Veteran Joins Health Technology Pioneer to Bring Prescription Digital Therapeutics for Type 2 Diabetes and other Cardiometabolic Conditions to Market Better Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, announced today that Diane Gomez-Thinnes joined the company as Chief Commercial Officer starting October 26, 2022. Gomez-Thinnes brings more than two decades of experience in the healthcare industry, leading the commercialization and launch of products spanning the medical device, prescription medicines and consumer health sect
Better Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Frank Karbe will join the company as President and Chief Executive Officer and serve as a member of the Board of Directors starting July 5th, 2022. Current CEO and company co-founder, Kevin Appelbaum, will continue to serve in that role until then. "I'm thrilled to welcome Frank to the Better Therapeutics team," said outgoing CEO Kevin Appelbaum. "Over the past seven years, I have had the privilege of assembling and leading an extraordinarily talented and committed t
Better Therapeutics, Inc. (NASDAQ:BTTX) (the "Company") announced today that the Company is terminating its employees and will explore strategic alternatives, including assignment for the benefit of creditors and/or a wind-down of the Company. This decision was made at a special meeting of the board of directors on Wednesday evening, March 13, 2024. Further, as previously disclosed, the Company's securities are subject to delisting from the Nasdaq Stock Market unless the Company presents a plan to regain compliance with Nasdaq's continued listing standards before the Nasdaq hearings panel. The Company has voluntarily requested a delisting of its securities and expects its securities to be d
One million prescriptions for AspyreRx will be offered to patients in underserved communities disproportionately affected by type 2 diabetes Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced a major partnership with the American College of Lifestyle Medicine's (ACLM) National Training Initiative (NTI), aimed at improving diabetes outcomes in underserved communities across the United States. Through this partnership, Better Therapeutics is committed to making one million prescriptions of its U.S. Food and Drug Administration (FDA)-authorized product, AspyreRx, available to support
Company to host sponsored education session on Saturday, March 09, 2024; Expanding access to a high quality and effective lifestyle modification intervention Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced the acceptance of a late-breaking abstract presenting 180-day outcomes data and its participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), to be held from March 6 to 9, 2024, in Florence, Italy. ATTD serves as a premier international forum showcasing cutting-edge advancements in diabetes care, bringing together clinicians
ORLANDO, FL / ACCESSWIRE / March 1, 2024 / RedChip Companies will air interviews with Better Therapeutics, Inc. (NASDAQ:BTTX) and Biotricity, Inc. (NASDAQ:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, March 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Better Therapeutics: https://www.redchip.com/assets/access/bttx_accessBiotricity: https://www.redchip.com/assets/access/btcy_accessFrank Karbe, CEO of Better Therapeutics, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. Better Therape
Company obtained FDA authorization for AspyreRxTM to treat adults with type 2 diabetes and announced commercial launch Company to host a conference call and webcast today at 8:30 a.m. ET Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today reported financial results for the third quarter 2023 and provided an update on progress towards achieving key corporate milestones. "We made tremendous progress in Q3, which included the FDA authorization of AspyreRx and the completion of the work required for a commercial launch in early October. AspyreRx offers healthcare providers a clinically proven, convenie
Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today announced it will release its third quarter 2023 financial results before the market opens on Thursday, November 09, 2023. Management will host a conference call and webcast to provide a business update at 8:30 a.m. ET / 5:30 a.m. PT on Thursday, November 09, 2023. To access the conference call, please register at: https://register.vevent.com/register/BI7ccccb1e37c44102b4f5ce26d785604d. Upon registering, each participant will be provided with call details and access codes. All participants are encouraged to join 10 minutes prior to the start time. The
Chardan Capital Markets initiated coverage of Better Therapeutics with a rating of Buy and set a new price target of $17.00
Cowen initiated coverage of Better Therapeutics with a rating of Outperform
4 - Better Therapeutics, Inc. (0001832415) (Issuer)
4 - Better Therapeutics, Inc. (0001832415) (Issuer)
4 - Better Therapeutics, Inc. (0001832415) (Issuer)
Gainers Cue Health (NASDAQ:HLTH) shares increased by 12.1% to $0.22 during Friday's after-market session. The company's market cap stands at $34.8 million. As per the press release, Q4 earnings came out 2 days ago. Aclarion (NASDAQ:ACON) shares increased by 10.39% to $0.44. The market value of their outstanding shares is at $3.1 million. BioSig Technologies (NASDAQ:BSGM) shares increased by 9.39% to $0.58. The market value of their outstanding shares is at $5.4 million. OptiNose (NASDAQ:OPTN) stock increased by 9.09% to $2.04. The company's market cap stands at $229.8 million. SCWorx (NASDAQ:WORX) stock rose 7.55% to $1.85. The market value of their outstanding shares is at $2.2 million
Shares of Jabil Inc. (NYSE:JBL) fell sharply during Friday’s session after the company reported financial second-quarter results and issued FY25 guidance below estimates. Jabil posted adjusted earnings of $1.68 per share, beating estimates of $1.66 per share. The company’s quarterly sales came in at $6.77 billion, missing expectations of $6.89 billion. Jabil shares dipped 14.2% to $126.56 on Friday. Here are some other stocks moving in today's mid-day session. Gainers Verb Technology Company, Inc. (NASDAQ:VERB) shares jumped 189% to $0.4047. VERB's MARKET.live launched Facebook and Instagram social shopping technology integration. Better Therapeutics, Inc. (NASDAQ:BTTX) surged 108
Gainers Better Therapeutics (NASDAQ:BTTX) shares increased by 65.4% to $0.06 during Friday's regular session. The market value of their outstanding shares is at $3.1 million. Carmell (NASDAQ:CTCX) shares rose 38.52% to $3.2. The market value of their outstanding shares is at $73.8 million. P3 Health Partners (NASDAQ:PIII) stock rose 38.23% to $0.98. The market value of their outstanding shares is at $112.5 million. Akebia Therapeutics (NASDAQ:AKBA) shares rose 28.1% to $1.75. The market value of their outstanding shares is at $330.6 million. The company's, Q4 earnings came out yesterday. Acrivon Therapeutics (NASDAQ:ACRV) shares increased by 26.03% to $6.39. The market value of their ou
EFFECT - Better Therapeutics, Inc. (0001832415) (Filer)
EFFECT - Better Therapeutics, Inc. (0001832415) (Filer)
EFFECT - Better Therapeutics, Inc. (0001832415) (Filer)